Myosin Inhibitors for Hypertrophic Obstructive Cardiomyopathy (HOCM): Is HOCM Passing Another Crossroads?

Can J Cardiol. 2024 May;40(5):820-823. doi: 10.1016/j.cjca.2024.01.034. Epub 2024 Feb 3.

Authors

Thorsten Lawrenz¹, Dennis Lawin², Christoph Stellbrink²

Affiliations

¹ Department of Cardiology and Intensive Care Medicine, University Hospital OWL of Bielefeld University, Campus Klinikum Bielefeld, Bielefeld, Germany. Electronic address: thorsten.lawrenz@klinikumbielefeld.de.
² Department of Cardiology and Intensive Care Medicine, University Hospital OWL of Bielefeld University, Campus Klinikum Bielefeld, Bielefeld, Germany.

PMID: 38311167
DOI: 10.1016/j.cjca.2024.01.034

No abstract available

Publication types

Editorial
Comment

MeSH terms

Benzylamines
Cardiomyopathy, Hypertrophic*
Humans
Myosins
Uracil / analogs & derivatives

Substances

MYK-461